Purpose: The role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) is described. Summary: The intrinsic resistance of NSCLC tumors to chemotherapy necessitates the ...

The immune microenvironment and heterogeneity of lung cancer tumours are the major barriers to immunotherapy, explains Lu. “We are looking to improve the efficacy of T cell therapy while ...

Active specific immunotherapy; BCG: Bacille Calmette–Guérin; KLH: Keyhole limpet hemocyanin; MPL: Monophosphoryl lipid A; NSCLC: Non-small-cell lung cancer. Various adjuvant products are ...

and lung. The term can apply to multiple types of specific therapies, including chemotherapy, radiation, hormone therapy, and immunotherapy. The main goal of adjuvant cancer treatments is to ...

Roche's drug is the first cancer immunotherapy to be approved by the FDA for adjuvant treatment of NSCLC ... and patients a new way to treat early lung cancer that has the potential to ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. The therapy, dubbed OST-HER2, uses a HER2 ...

Experts from various tumor fields, including lung cancer, hepatobiliary ... effectiveness and high safety of the 'neo-adjuvant bladder preservation immunotherapy model' with Chinese characteristics.

In the longer-term, the team believes that this work could lead to more successful combination therapies involving radiotherapy and immunotherapy, which could improve outcomes in high-risk breast ...

Or the melanoma was thicker than 4mm and not ulcerated stage 2C - this means it is thicker than 4 mm and is ulcerated You have an immunotherapy drug called pembrolizumab (Keytruda). A nurse gives it ...